Gen-Probe acquired GTI from the Riverside Company, a global private equity firm, and from individual investors who include the company’s founders and management.
Gen-Probe president and CEO Carl Hull said acquiring GTI enables them to broaden and strengthen their transplant diagnostics business.
"In addition, the acquisition gives us access to growing coagulation and transfusion-related blood bank products that we can sell to our current customer base," Hull said.
GTI develops and manufactures the human leukocyte antigen (HLA) antibody detection products sold by Gen-Probe under its Lifecodes brand.
GTI also commercializes a number of other HLA-related testing products, including serological typing trays, enzyme immunoassays (EIAs), and a range of molecular typing products for donor-recipient matching and patient monitoring.
